Tocilizumab in systemic sclerosis treatment: a case report

Area of Science:

• Rheumatology
• Immunology
• Pulmonology

Background:

• Systemic sclerosis is a chronic autoimmune disease characterized by fibrosis of the skin and internal organs, including the lungs.
• Interstitial lung disease (ILD) is a common and serious complication of systemic sclerosis, leading to significant morbidity and mortality.
• Tocilizumab, an interleukin-6 receptor inhibitor, has gained attention for its potential therapeutic benefits in autoimmune and inflammatory conditions.

Observation:

• A case study involving a 44-year-old female with systemic sclerosis and recent-onset breathlessness is presented.
• The patient received tocilizumab 162 mg subcutaneously every two weeks.
• Clinical assessment included a modified Rodnan skin score, which was initially 18.

Findings:

• Tocilizumab treatment resulted in a decrease in the modified Rodnan score within 4 weeks.
• The patient completed 6 months of tocilizumab therapy without reported side effects.
• The treatment appeared to maintain lung function, preventing further decline.

Implications:

• Tocilizumab demonstrates potential efficacy in managing skin fibrosis and preserving lung function in systemic sclerosis.
• The observed safety profile suggests tocilizumab may be a viable treatment option for patients with systemic sclerosis and related ILD.
• These findings support the advancement of tocilizumab as a novel therapeutic strategy, potentially ushering in a new era for systemic sclerosis treatment.